“A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers”
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum- tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety and tolerability of ZW49. Eligible patients include those with locally advanced (unresectable) or metastatic HER2-expressing cancers.
Drug - ZW49
Dose Escalation: ZW49 administration IV Q2W or Q3W at dose levels determined by the SMC Expansion: MTD(s) or RD(s) identified in the dose-escalation part of the study
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers